Iovance Biotherapeutics Raises 2026 Revenue Outlook

Iovance Biotherapeutics Inc raised its full-year 2026 revenue outlook to between $410 million and $420 million, causing shares to surge more than 14% in premarket trading on Tuesday. The revised midpoint represents a $55 million increase over previous guidance and exceeds the Wall Street consensus analyst estimate of $402.8 million.

Management attributed the growth to sustained sales of Proleukin and strong domestic adoption of Amtagvi, a tumor-infiltrating lymphocyte therapy. To maintain this momentum, the company expanded its authorized treatment center network to approximately 100 locations, with a target of reaching at least 110 centers by the end of 2026.

Iovance is also advancing clinical trials for lifileucel to obtain regulatory approvals for additional solid tumor indications.